NZ521076A

NZ521076A - Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation

Info

Publication number: NZ521076A
Application number: NZ521076A
Authority: NZ
Inventors: Daniel Achard; Herve Bouchard; Jean Bouquerel; Bruno Filoche; Serge Grisoni; Augustin Hittinger; Michael Myers
Original assignee: Aventis Pharma Sa
Priority date: 2000-03-03
Filing date: 2001-03-01
Publication date: 2004-08-27
Also published as: IL151209A; MA26879A1; UA72319C2; EE200200486A; DE60142890D1; EP1263721A1; ZA200206916B; CA2400138A1; OA12221A; SI1263721T1; AR034405A1; PT1263721E; WO2001064633A1; IL151209A0; HUP0300350A2; NO324523B1; EP1263721B1; CN1411440A; KR100813740B1; DK1263721T3

Abstract

A compound of formula (I), its preparation and pharmaceutical compositions containing as active ingredient a compound of formula (I) are disclosed, wherein: R1 represents a -NHCOR4 or -N(R5)-Y-R6 radical; Y is SO2; R4 represents an -alk-SO2R11, -alk-SO2-CH=CH-R11, Het substituted by -SO2R11 or phenyl substituted by -SO2-R11 or -alk-SO2-R11 radical; R5 represents a hydrogen atom or an alkyl radical; R6 represents a phenylalkyl radical, Het or Ar; wherein alk, Ar and R11 are as defined in the specification.

Description

<div class="application article clearfix" id="description"> New Zealand Paient Spedficaiion for Paient Number 521 076 PHARMACEUTICAL COMPOSITIONS CONTAINING 3-AMINO-AZETIDINE DERIVATIVES, NOVEL DERIVATIVES. AND PREPARATION THEREOF The present invention relates to pharmaceutical compositions containing, as active ingredient,- at least one compound of formula: ' 10 n- (I) a or one of its-pharmaceutically acceptable salts, to the novel derivatives of formula (i), to their pharmaceutically acceptable salts and to their 15 preparation. The compound of formula (I) for which R2 and r3 .represent phenyl radicals, ri 'represents : a radical. , -n (r5) -y-r6, y is S02, rc represents a methyl . radical and ' Rg represents a phenyl radical is described as a • ' 20 synthesis intermediate in Patent WO 99/01451. The other ■ compounds and their pharmaceutically acceptable salts are .'novel and as such form parts of the invention. - 'ntellectual property office of n.z. -5 2004 RECEIVED The present invention provides a pharmaceutical composition containing, as active 1. Pharmaceutical composition containing, as active ingredient, a compound of formula: N (I) in which Rx represents a radical -NHCOR4 or -N(R5)-Y-R6, Y is S02, R2 and R3, which are identical or different, represent either phenyl which is substituted with one or more halogen atoms; or a heteroaromatic chosen from pyrimidinyl and pyridyl; R4 represents a radical -alk-S02-Rn, -alk-S02-CH=CH-R1;L, Het substituted with -S02-Rn or phenyl substituted with -SO2-R11 or -alk-S02-Rn, R5 represents a hydrogen atom or an alkyl radical, R6 represents a phenylalkyl, Het or Ar radical, Ru represents an alkyl, Ar or Het radical, - 9 jun 2m ^ RECEIVED intellectual property office of n.z. 3 Ar represents a phenyl or naphthyl radical, these radicals being optionally substituted with one or more halogen atoms or alkyl, alkoxy, cyano, CF3, -S02NH2, -NH-COCH3 or Het radicals, or alternatively Het 5 represents a 3- to 10-membered unsaturated or saturated mono- or bicyclic heterocycle containing one or more heteroatoms chosen from oxygen, sulfur and nitrogen optionally substituted with one or more halogen atoms or alkyl or vinyl radicals, 10 alk represents an alkyl or alkylene radical, the alkyl and alkylene radicals and portions and the alkoxy radicals and portions are in the form of a straight or branched chain and contain 1 to 6 carbon atoms, 15 an optical isomer of such a compound or one of its pharmaceutically acceptable salts. In the preceding definitions and in those which follow, unless otherwise stated, the alkyl and alkylene radicals and portions and the alkoxy radicals 2 0 and portions are in the form of a straight or branched chain and contain 1 to 6 carbon atoms and the cycloalkyl radicals contain 3 to 10 carbon atoms. Among the alkyl radicals, there may be mentioned the methyl, ethyl, n-propyl, isopropyl, n-25 butyl, sec-butyl, iso-butyl, tert-butyl, pentyl and hexyl radicals. Among the alkoxy radicals, there may be intellectual property office of n.z. - 9 jun im a ■> 1 ti 4 mentioned the methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy and pentyloxy radicals. Among the cycloalkyl radicals, there may be 5 mentioned the cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl radicals. The term halogen comprises chlorine, fluorine, bromine and iodine. Among the heterocycles represented by Het, 10 the following heterocycles may be mentioned: benzimidazole, benzoxazole, benzothiazole, benzothiophene, cinnoline, thiophene, quinazoline, quinoxaline, quinoline, pyrazole, pyrrole, pyridine, imidazole, indole, isoquinoline, pyrimidine, thiazole, 15 thiadiazole, piperidine, piperazine, pyrrolidine, triazole, furan, tetrahydroisoquinoline, tetrahydroquinoline, these heterocycles being optionally substituted with one or more halogen atoms or alkyl, alkoxy, vinyl, alkoxycarbonyl, oxo, hydroxyl, 20 0CF3 or CF3 radicals. The compounds of formula (I) may be provided in the form of enantiomers and of diastereoisomers. These optical isomers and mixtures thereof also form part of the invention. 2 5 Preferably, in the pharmaceutical composition of the invention, the compound of formula (I) is one in which: Ri represents a radical -N(R5)-Y-R6, intellectual property office of n.z. - 9 jun im . « A P I II P 5 Y, R2, R3, R4, R5, Rg, Ar and alk are as defined above; and Het is chosen from thiophene, quinoline, pyridine and pyrrolidine, these heterocycles being optionally substituted with one or more halogen atoms or alkyl or 5 vinyl radicals. novel. Accordingly, the invention further provides a compound of formula (I): in which Ri represents a radical -NHCOR4 or -N(R5)-Y-R6, Y is S02, R2 and R3, which are identical or different, represent either a phenyl which is substituted with one 15 or more halogen atoms, or a heteroaromatic chosen from pyrimidinyl and pyridyl, R4 represents a radical -alk-S02-Rn, -alk-S02-CH=CH-R11, Het substituted with -S02-Rn or phenyl substituted with -S02-Rh or -alk-S02-Rn, 2 0 R5 represents a hydrogen atom or an alkyl radical, Rs represents a phenylalkyl, Het or Ar radical, Rn represents an alkyl, Ar or Het radical, Ar represents a phenyl or naphthyl radical, these radicals being optionally substituted with one or more Some of the compounds of formula (I) are 10 (I) intellectual property office of n.Z. - 9 jun 2004 6 halogen atoms or alkyl, alkoxy, cyano, CF3, -S02NH2/ -NH-COCH3 or Het radicals, or alternatively, Het represents a 3- to 10-membered unsaturated or saturated mono- or bicyclic heterocycle containing one 5 or more heteroatoms chosen from oxygen, sulfur and nitrogen optionally substituted with one or more halogen atoms or alkyl or vinyl radicals; alk represents an alkyl or alkylene radical, the alkyl and alkylene radicals and portions and the 10 alkoxy radicals and portions are in the form of a straight or branched chain and contain 1 to 6 carbon atoms, an optical isomer of such a compound or one of its pharmaceutically acceptable salts, with the exception of the compound for which for which 15 R2 and R3 represent phenyl radicals, Ri represents a radical -N(R5)-Y-R6, Y is S02, R5 represents a methyl radical and R6 represents a phenyl radical. In one embodiment Het is chosen from 2 0 thiophene, quinoline, pyridine, imidazole, and pyrrolidine, these heterocycles being optionally substituted with one or more halogen atoms or alkyl. In a further embodiment Ri represents a 25 radical -N(R5)-Y-R6; Y, R2, R3, R5, R6/ Ru and Ar are as defined above and Het is chosen from thiophene, quinoline, pyridine, imidazole and pyrrolidine, these heterocycles being optionally substituted with one or intellectual PROPERTY office of n.Z. - 9 jun 200"! 7 more halogen atoms or alkyl radicals, their optical isomers and their pharmaceutically acceptable salts, with the exception of the compound in which R2 and R3 represent phenyl radicals, Ri represents a radical 5 -N(R5)-Y-R6, Y is S02, R5 represents a methyl radical and R6 represents a phenyl radical. Specific examples of compounds of the invention are as follows: 10 N-{1-[bis(4-chlorophenyl)-methyl]azetidin-3-yl}thien-2 -ylsulfonamide N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-4 -methoxyphenylsulfonamide N- [4- (N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-15 yl}sulfamoyl)phenyl]acetamide N- {1- [bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-methylphenyl-sulfonamide N-{1- [bis(4-chlorophenyl)methyl]azetidin-3-yl}-3,4-dimethoxyphenylsulfonamide 20 N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-fluorophenyl-sulfonamide N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3,4-dichlorophenylsulfonamide N- {1- [bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-2 5 cyanophenylsulfonamide N-{1- [bis(4-chlorophenyl)methyl]azetidin-3-yl}-2,5-dimethoxyphenylsulfonamide intellectual property office of n.i- - 9 jun 20m DECEIVED 8 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3 -trifluoromethylsulfonamide N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-ylJnaphth-2 -yl-sulfonamide N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}naphth-l-yl-sulfonamide N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3,4 -di fluorophenylsulfonamide N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-1-me t hy 1 -1 - H- imi da z o 1 - 4 - y 1 sul f onami de N- [4- (N- {1- [bis(4-chlorophenyl)methyl]azetidin-3-yl}sulfamoyl)-2-chlorophenyl]acetamide N- {1- [bis(4-chlorophenyl)methyl] azetidin-3-yl}pyrid-3 -ylsulfonamide N-{l- [bis(4-chloro-phenyl)methyl]azetidin-3-yl}-4-fluorophenylsulfonamide N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}quinol-8-ylsulfon-amide N- {1- [bis(4-chlorophenyl)methyl]azetidin-3-yl}phenylsulfonamide N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}(phenyl-methyl)sulfonamide N-{1- [bis(4-chlorophenyl)methyl]-azetidin-3-yl}-3,5-difluorophenylsulfonamide N- {l- [bis(4-chlorophenyl)methyl]-azetidin-3-yl}pyrid-2-sulfonamide N- {l- [bis(4-chlorophenyl)-methyl]azetidin-3-yl}-(3-fluoro-5-pyrrolidin-1-ylphenyl)sulfonamide intellectual property office of n.z. - 9 jun 2004 _ mm N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-methyl-4 -fluorophenylsulfonamide N-{1-[bis(4-chlorophenyl)-methyl]azetidin-3-yl}-N-methylquinol-8-ylsulfonamide N-{l-[bis(4-chlorophenyl)-methyl]azetidin-3-yl}-N-methylphenylsulfonamide N-{l-[bis(4-chlorophenyl)-methyl]azetidin-3-yl}-N-methyl(phenylmethyl)sulfonamide N-{l-[bis(4-chlorophenyl)-methyl]azetidin-3-yl}-3-sulfamoylphenylsulfonamide 2-Benzenesulfonyl-N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}acetamide N-{1-[bis(4-chlorophenyl)methyl]-azetidin-3-yl}-2-(toluene-4-sulfonyl)acetamide (3-chloro-4-methylsulfonylthiophene-2-carboxy)-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}amide N-{1- [bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-(2-phenylethylenesulfonyl)propionamide N-{l- [bis(4-chlorophenyl)-methyl]azetidin-3-yl}-4-methylsulfonylbenzamide N-{l-[bis(4-chlorophenyl)-methyl]azetidin-3-yl}-4-methanesulfonylbenzamide (5-methylsulfonylthiophene-2-carboxy)-{l- [bis (4-chlorophenyl)methyl]azetidin-3-yl}amide (5-methylsulfonyl-3-methyl-4-vinylthiophene-2 -carboxy){l-[bis-(4-chlorophenyl)-methyl]azetidin-3-yl}amide INTELLECTUAL PROPER"^ OFFICE OF N.2- - 9 m 2004 received 10 (5-methylsulfonyl-3-methyl-4-vinylthiophene-2-carboxy){l-[bis(4-chlorophenyl)-methyl]azetidin-3-yl}amide N-{l-[bis(4-chlorophenyl)pyridin-3-ylmethyl]azetidin-3-yl}-3,5-difluorobenzenesulfonamide N-{l-[bis(4-Chlorophenyl)pyrimidin-5-ylmethyl]azetidin-3-yl}-3,5-difluorobenzenesulfonamide intellectual property office of n.z. , - 9 jun 2004 received 11 The compounds of formula (I) for which Ri represents a radical -NHCOR4 may be prepared according to the following reaction scheme: In these formulae, R2, R3 and R4 have the same meanings as in formula (I). Step a is generally carried out in an inert solvent such as tetrahydrofuran, dioxane, a chlorinated solvent (for example dichloromethane or chloroform), at a temperature of between 15 and 3 0°C, in the presence of a base such as a trialkylamine (for example intellectual property office of n.z. - 9 jun 2004 received 12 triethylamine or dipropylethylamine) or in pyridine, at a temperature of between 0 and 30°C. Step b is preferably carried out in methanol, in an autoclave, at a temperature of between 50 and 5 7 0 ° C . Step c is generally carried out in the presence of a condensing agent used in peptide chemistry, such as a carbodiimide (for example 1-(3-dimethylamiopropyl)-3-ethylcarbodiimide or 10 N,N'-dicyclohexylcarbodiimide) or N,N'carbonyl- diimidazole, in an inert solvent such as an ether (for example tetrahydrofuran or dioxane) , an amide (dimethylformamide) or a chlorinated solvent (for example methylene chloride, 1,2-dichloroethane or 15 chloroform) at a temperature of between 0°C and the boiling point of the reaction mixture. It is also possible to use a reactive derivative of the acid such as an acid chloride, optionally in the presence of an acid acceptor such as a nitrogen-containing organic 20 base (for example trialkylamine, pyridine, 1,8-diaza-bicyclot5.4.0]undec-7-ene or 1,5-diazabicyclo[4.3.0]-non-5-ene), in a solvent as cited above, or a mixture of these solvents, at a temperature of between 0°C and the boiling point of the reaction mixture. 25 The derivatives R4COOH are commercially available or may be obtained according to the methods described in R.C. LAROCK, Comprehensive Organic Transformations, VCH editor. 13 The azetidinols of formula 1 may be obtained by application or adaptation of the methods described by KATRITZKY A.R. et al. , J. Heterocycl. Chem. , 271 (1994) or DAVE P.R., J. Org. Chem., 61, 5453 (1996) and in the examples. The procedure is generally carried out according to the following reaction scheme: 0 3 ' 2 HYDROXYUVMINE N .OH FL B Br R3 R2 R. r2 o I in these formulae, R2 and R3 have the same meanings as 10 in formula (I) and Hal represents a chlorine or bromine atom. In step A, the procedure is preferably carried out in an inert solvent such as a 1-4C aliphatic alcohol (for example ethanol or methanol), 15 optionally in the presence of an alkali metal hydroxide, at the boiling point of the reaction medium. 14 In step B, the reduction is generally carried out by means of lithium aluminum hydride, in tetrahydrofuran at the boiling point of the reaction medium. 5 In step C, the procedure is preferably carried out in an inert solvent such as a 1-4C aliphatic alcohol (for example ethanol or methanol), in the presence of sodium hydrogen carbonate, at a temperature of between 20°C and the boiling point of 10 the reaction medium. In step D, the procedure is carried out according to the method described by GRISAR M. et al. in J. Med. Chem., 885 (1973). The magnesium compound of the brominated derivative is formed and then the 15 nitrile is caused to react, in an ether such as ethyl ether, at a temperature of between 0°C and the boiling point of the reaction medium. After hydrolysis with an alcohol, the intermediate imine is reduced in situ with sodium borohydride at a temperature of between 0°C and 20 the boiling point of the reaction medium. The derivatives R2-CO-R3 are commercially available or may be obtained by application or adaptation of the methods described by KUNDER N.G. et al. J. Chem. Soc. Perkin Trans 1, 2815 (1997); MORENO-2 5 MARRAS M., Eur. J. Med. Chem., 23_ (5) 477 (1988); SKINNER et al. , J. Med. Chem., _14_ (6) 546 (1971); HURN N.K., Tet. Lett., 36 (52) 9453 (1995); MEDICI A. et al., Tet. Lett., 24_ (28) 2901 (1983); RIECKE R.D. et 15 al., J. Org. Chem., 62 (20) 6921 (1997); KNABE J. et al., Arch. Pharm., 306 (9) 648 (1973); CONSONNI R. et al. , J. Chem. Soc. Perkin Trans 1, 1809 (1996); FR-96-2481 and JP-94-261393. 5 The derivatives RsBr are commercially available or may be obtained by application or adaptation of the methods described by BRANDSMA L. et al. , Synth. Comm., 2_0 (11) 1697 and 3153 (1990); LEMAIRE M. et al., Synth. Comm., 24 (1) 95 (1994); 10 GODA H. et al., Synthesis, 9 849 (1992); BAEUERLE P. et al., J. Chem. Soc. Perkin Trans 2, 489 (1993) . The derivatives R2CN are commercially available or may be obtained by application or adaptation of the methods described by BOUYSSOU P. et 15 al., J. Het. Chem., 29 (4) 895 (1992); SUZUKI N. et al., J. Chem. Soc. Chem. Comm., 1523 (1984); MARBURG S. et al., J. Het. Chem., 17 1333 (1980); PERCEC V. et al., J. Org. Chem., ^0 (21) 6895 (1995). The compounds of formula (I) for which Ri 20 represents a radical -N(R5)-Y-R6 may be prepared according to the following reaction scheme: 16 n- NmH„ Hal-Y-RR a n- R„ n- |b nh-y-r6 Hal-alk n Ic \ Y-R„ alk in these formulae, Y, R2, R3 and R6 have the same meanings as in formula (I), Hal represents a halogen atom and, preferably, an iodine, chlorine or bromine 5 atom. Step a is generally carried out in an inert solvent such as tetrahydrofuran, dioxane or a chlorinated solvent (for example dichloromethane or chloroform), in the presence of an amine such as a 10 trialkylamine (for example triethylamine), at a temperature of between 5°C and 20°C. Step b is generally carried out in an inert solvent such as tetrahydrofuran, in the presence of sodium hydride, at a temperature of 0°C and the boiling 15 point of the reaction medium. The Hal-SC>2R6 derivatives are commercially available or may be obtained by halogenation of the corresponding sulfonic acids, in particular in situ in the presence of chlorosulfonyl isocyanate and alcohol, 17 in a halogenated solvent (for example dichloromethane or chloroform). The Hal-C0-R6 derivatives are commercially available or may be prepared according to the methods 5 described in R. C. LAROCK, Comprehensive Organic Transformations, VCH editor. The compounds of formula (I) may also be prepared according to the following reaction scheme: r2-co-r3 R3Br + R2-CHO HN- R2-CHOH-R3 R2—CHBi R, e R, N- Id Ri 10 Nile X In these formulae, Ri, R2 and R3 have the same meanings as in formula (I) and Ph represents a phenyl. Step a is generally carried out in an alcohol 15 such as methanol, in the presence of sodium borohydride, at a temperature in the region of 20°C. 18 In step b, the magnesium compound of the brominated derivative is prepared and it is caused to react, in an inert solvent such as ethyl ether or tetrahydrofuran, at a temperature of between 0°C and 5 the boiling point of the reaction medium. Step c is carried out by means of a halogenating agent such as hydrobromic acid, thionyl bromide, thionyl chloride, a mixture of triphenylphosphine and carbon tetrabromide or 10 tetrachloride, in acetic acid or an inert solvent such as dichloromethane, chloroform, carbon tetrachloride or toluene, at a temperature of between 0°C and the boiling point of the reaction medium. Step d is carried out by means of hydrogen, 15 in the presence of palladized charcoal, in an alcohol such as methanol, at a temperature in the region of 2 0 ° C . Step e is carried out in an inert solvent such as acetonitrile, in the presence of an alkali 20 metal carbonate (for example potassium carbonate) and potassium iodide, at a temperature of between 20°C and the boiling point of the reaction medium. The derivatives RsBr and the derivatives R2-CHO are commercially available or may be obtained 25 according to the methods described for example by R.C. LAROCK, Comprehensive Organic Transformations, VCH editor. 19 The compounds of formula (I) for which Rx represents a radical -N(R5)-Y-R6 in which R6 is a phenyl radical substituted with a hydroxyl radical may also be 5 prepared by hydrolysis of a corresponding compound of formula (I) for which Rx represents a radical -N(R5)-Y-R6 in which Rs is a phenyl radical substituted with an alkoxy radical. 10 This hydrolysis is generally carried out in an inert solvent such as a chlorinated solvent (for example dichloromethane or chloroform), by means of boron tribromide, at a temperature in the region of 20°C. 15 The compounds of formula (I) for which Rx represents a radical -N(R5)-Y-R6 in which R6 is a phenyl radical substituted with a 1-pyrrolidinyl radical may also be prepared by the action of pyrrolidine and of a intellectual property office of n.z. - 9 jun 2004 received 20 corresponding compound of formula (I) for which Rx represents a radical -N(R5)-Y-R6 in which R6 is a phenyl radical substituted with a fluorine atom. This reaction is preferably carried out in an 5 inert solvent such as dimethyl sulfoxide, at a temperature of 90°C. It is understood for persons skilled in the art that, to carry out the processes according to the invention which are described above, it may be 10 necessary to introduce groups protecting amino, hydroxyl and carboxyl functions in order to avoid side reactions. These groups are those which allow removal without affecting the rest of the molecule. As examples of groups protecting the amino function, there may be 15 mentioned tert-butyl or methyl carbamates which may be regenerated using iodotrimethylsilane or allyl using palladium catalysts. As examples of groups protecting the hydroxyl function, there may be mentioned triethylsilyl and tert-butyldimethylsilyl which may be 20 regenerated using tetrabutylammonium fluoride or alternatively asymmetric acetals (methoxymethyl or tetrahydropyranyl for example) with regeneration using hydrochloric acid. As groups protecting carboxyl functions, there may be mentioned esters (allyl or 25 benzyl for example), oxazoles and 2-alkyl-l,3- oxazolines. Other protecting groups which can be used are described by GREENE T.W. et al., Protecting Groups 21 in Organic Synthesis, second edition, 1991, John Wiley & Sons. The compounds of formula (I) may be purified by the customary known methods, for example by 5 crystallization, chromatography or extraction. The enantiomers of the compounds of formula (I) may be obtained by resolution of the racemates for example by chromatography on a chiral column according to PIRCKLE W.H. et al'. , Asymmetric synthesis, Vol. 1, 10 Academic Press (1983) or by formation of salts or by synthesis from chiral precursors. The diastereoisomers may be prepared according to known conventional methods (crystallization, chromatography or from chiral precursors). 15 The compounds of formula (I) may be optionally converted to addition salts with an inorganic or organic acid by the action of such an acid in an organic solvent such as an alcohol, a ketone, an ether or a chlorinated solvent. These salts also form 20 part of the invention. As examples of pharmaceutically acceptable salts, the following salts may be mentioned: benzenesulfonate, hydrobromide, hydrochloride, citrate, ethanesulfonate, fumarate, gluconate, iodate, 25 isethionate, maleate, methanesulfonate, methylene-bis-P-oxynaphthoate, nitrate, oxalate, pamoate, phosphate, salicylate, succinate, sulfate, tartrate, theophyllineacetate and p-toluenesulfonate. 22 The compounds of formula (I) exhibit advantageous pharmacological properties. These compounds possess a high affinity for the cannabinoid receptors and particularly those of the CB1 type. They 5 are CBl-receptor antagonists and are therefore useful in the treatment and prevention of disorders affecting the central nervous system, the immune system, the cardiovascular or endocrine system, the respiratory system, the gastrointestinal apparatus and reproductive 10 disorders (Hollister, Pharm. Rev.; 38, 1986, 1-20, Reny and Sinha, Prog. Drug Res., 36, 71-114 (1991), Consroe and Sandyk, in Marijuana/Cannabinoids, Neurobiology and Neurophysiology, 459, Murphy L. and Barthe A. Eds, CRC Press, 1992). 15 Accordingly, these compounds may be used for the treatment or prevention of psychoses including schizophrenia, anxiety disorders, depression, epilepsy, neurodegeneration, cerebellar and spinocerebellar disorders, cognitive disorders, cranial trauma, panic 20 attacks, peripheral neuropathies, glaucomas, migraine, Parkinson's disease, Alzheimer's disease, Huntington's chorea, Raynaud's syndrome, tremor, obsessive-compulsive disorder, senile dementia, thymic disorders, Tourette's syndrome, tardive dyskinesia, bipolar 25 disorders, cancers, movement disorders induced by medicaments, dystonia, endotoxemic shocks, hemorrhagic shocks, hypotension, insomnia, immunological diseases, multiple sclerosis, vomiting, asthma, appetite 23 disorders (bulimia, anorexia), obesity, memory disorders, in weaning from chronic treatments and alcohol or drug abuse (opioids, barbiturates, cannabis, cocaine, amphetamine, phencyclide, hallucinogens, 5 benzodiazepines for example), as analgesics or potentiators of the analgesic activity of the narcotic and nonnarcotic drugs. They may also be used for the treatment or prevention of intestinal transit. The affinity of the compounds of formula (I) 10 for the cannabis receptors has been determined according to the method described by KUSTER J.E., STEVENSON J.I., WARD S.J., D1AMBRA T.E., HAYCOCK D.A. in J. Pharmacol. Exp. Ther., 2 64 1352-1363 (1993) . In this test, the IC50 of the compounds of 15 formula (I) is less than or egual to 1000 nM. Their antagonist activity has been shown by means of the model of hypothermia induced by an agonist of the cannabis receptors (CP-55940) in mice, according to the method described by Pertwee R.G. in Marijuana, 20 Harvey D.J. eds, 84 Oxford IRL Press, 263-277 (1985) . In this test, the ED50 of the compounds of formula (I) is less than or egual to 50 mg/kg. The compounds of formula (I) exhibit low toxicity. Their LD50 is greater than 40 mg/kg by the 25 subcutaneous route in mice. The following examples illustrate the invention. 24 Example 1 69.3 mm3 of triethylamine and 110 mg of thien-2-ylsulfonyl chloride are successively added, at room temperature and under an argon atmosphere, to a 5 solution of 61.4 mg of 1-[bis(4-chlorophenyl)methyl]-azetidin-3-ylamine in 3 cm3 of dichloromethane. After stirring for 68 hours at room temperature, the reaction mixture is introduced into a Bond Elut® SCX cartridge (3 cm5/500 mg) , eluting successively with twice 2 cm3 of 10 dichloromethane and then twice 2 cm3 of a 1 M solution of ammonia in methanol. The ammoniacal fractions are pooled and concentrated to dryness under reduced pressure (2.7 kPa). The residue obtained is dissolved in 5 cm3 of dichloromethane, washed with three times 15 3 cm3 of distilled water, dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure (2.7 kPa). 60 mg of N-{1-[bis(4-chlorophenyl)-methyl]azetidin-3-yl}thien-2-ylsulfonamide are thus obtained in the form of a cream-colored foam [1H NMR 20 spectrum (300 MHz, CDC13, 8 in ppm) : 2.77 (split t, J = 7 and 2 Hz : 2H); 3.40 (split t, J = 7 and 2 Hz : 2H); 4.06 (mt : 1H); 4.21 (s : 1H); from 4.85 to 5.25 (broad unresolved complex : 1H); 7.06 (t, J = 4.5 Hz : 1H); from 7.15 to 7.35 (mt : 8H); 7.58 (mt : 2H)]. 2 5 1-[Bis(4-chlorophenyl)methyl]azetidin-3-yl- amine may be obtained in the following manner: 400 cm3 of a mixture of methanol and liquid ammonia (50/50 by volume) are added to 27 g of 1-[bis(4-chlorophenyl)- 25 methyl]azetidin-3-yl methylsulfonate contained in an autoclave previously cooled to around -60°C. The reaction medium is then stirred at 60°C for 24 hours and then abandoned in the open air to allow the 5 evaporation of the ammonia and finally concentrated under reduced pressure (2.7 kPa). The residue is taken up in 500 cm3 of a 0.37 N aqueous sodium hydroxide solution and extracted with four times 500 cm of ethyl ether. The combined organic phases are washed 10 successively with twice 100 cm3 of distilled water and 100 cm3 of a saturated sodium chloride solution, dried over magnesium sulfate, filtered and concentrated under reduced pressure (2.7 kPa). The residue obtained is purified by flash chromatography on silica gel [eluant: 15 dichloromethane/methanol (95/5 by volume)]. 14.2 g of 1-[bis(4-chlorophenyl)methyl]azetidin-3-ylamine are obtained in the form of an oil which solidifies into a cream-colored solid. 1-[Bis(4-chlorophenyl)methyl]azetidin-3-yl 20 methylsulfonate may be prepared in the following manner: 3.5 cm3 of methylsulfonyl chloride are added, under argon over 10 minutes, to a solution of 12 g of 1-[bis(4-chlorophenyl)methyl]azetidin-3-ol in 200 cm3 of dichloromethane and then the mixture is cooled to +5°C 25 and 3.8 cm3 of pyridine are poured in over 10 minutes. After stirring for 30 minutes at +5°C and then for 20 hours at 20°C, the reaction mixture is diluted with 100 cm3 of water and 100 cm3 of dichloromethane. The 26 mixture, which is first filtered, is separated after settling. The organic phase is washed with water and then dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure 5 (2.7 kPa). The oil obtained is chromatographed on a silica gel column (particle size 0.063-0.200 mm, height 40 cm, diameter 3.0 cm), eluting under an argon pressure of 0.5 bar with a mixture of cyclohexane and ethyl acetate (70/30 by volume) and collecting 100-cm3 10 fractions. Fractions 4 to 15 are combined and concentrated to dryness under reduced pressure (2.7 kPa). 6.8 g of 1-[bis(4-chlorophenyl)methyl]-azetidin-3-yl ester of methylsulfonic acid are obtained in the form of a yellow oil. 15 1-[Bis(4-chlorophenyl)methyl]azetidin-3-ol may be prepared according to the procedure described by KATRITZKY A.R. et al., J. Heterocycl. Chem., 271 (1994), starting with 35.5 g of [bis(4- chlorophenyl)methyl]-amine hydrochloride and 11.0 cm3 of 20 epichlorohydrin. 9.0 g of l-[bis(4- chlorophenyl)methyl]azetidin-3-ol are isolated. [Bis(4-chlorophenyl)methyl]amine hydrochloride may be prepared according to the method described by GRISAR M. et al., J. Med. Chem., 885 25 (1973) . Example 2 By carrying out the operation according to the procedure of Example 1, but starting with 124 mg of 27 4-methoxyphenylsulfonyl chloride, 12 mg of N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-methoxyphenylsulfonamide are obtained in the form of a cream-colored lacquer [1H NMR spectrum (300 MHz, 5 CDCI3, 5 in ppm): 2.70 (split t, J = 7 and 2 Hz : 2H); 3.35 (split t, J = 7 and 2 Hz : 2H); 3.85 (s : 3H); 3.94 (mt : 1H); 4.18 (s : 1H); 4.83 (d, J = 9 Hz : 1H); 6.94 (broad d, J = 9 Hz : 2H); 7.22 (s : 8H); 7.75 (broad d, J = 9 Hz : 2H)]. 10 Example 3 By carrying out the operation according to the procedure of Example 1, but starting with 140 mg of 4-acetamidophenylsulfonyl chloride, 13 mg of N-[4-(N-{1-[bis(4-chlorophenyl)methyl]azetidin-15 3-yl}sulfamoyl)phenyl]acetamide are obtained in the form of a cream-colored lacquer [1H NMR spectrum (300 MHz, CDCI3, 5 in ppm): 2.26 (s : 3 H) ; 2.74 (split t, J = 7 and 2 Hz : 2H); 3.39 (split t, J = 7 and 2 Hz : 2H); 4.01 (mt : 1H); 4.22 (s : 1H); 4.92 (d, 20 J = 9 Hz : 1H); 7.32 (mt : 8H); 7.49 (broad s : 1H); 7.68 (broad d, J = 9 Hz : 2H); 7.81 (broad d, J = 9 Hz : 2H)]. Example 4 By carrying out the operation according to 25 the procedure of Example 1, but starting with 114 mg of 4-methylphenylsulfonyl chloride, 19 mg of N-{l-[bis-(4-chlorophenyl)methyl]azetidin-3-yl}-4-methylphenyl-sulfonamide are obtained in the form of a colorless 28 lacquer [1H NMR spectrum (300 MHz, CDC13, S in ppm) : 2.42 (s : 3H); 2.71 (split t, J = 7 and 2 Hz : 2H); 3.36 (split t, J = 7 and 2 Hz : 2H); 3.97 (mt : 1H); 4.19 (s : 1H); 4.81 (d, J = 9.5 Hz : 1H); from 7.15 to 5 7.40 (mt : 10H); 7.71 (broad d, J = 8.5 Hz : 2H)]. Example 5 By carrying out the operation according to the procedure of Example 1, but starting with 142 mg of 3,4-dimethoxyphenylsulfonyl chloride, 10 mg of 10 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}- 3,4-dimethoxyphenylsulfonamide are obtained in the form of a cream-colored lacquer [1H NMR spectrum (300 MHz, CDCI3, 8 in ppm): 2.72 (broad t, J = 7.5 Hz : 2H); 3.37 (broad t, J = 7.5 Hz : 2H); from 3.85 to 4.00 15 (mt : 1H) ; 3.91 (s : 3H) ; 3.93 (s : 3H); 4.19 (s : 1H) ; 4.84 (d, J = 9 Hz : 1H); 6.90 (d, J = 8.5 Hz : 1H); 7.23 (mt : 8H); 7.29 (d, J = 2 Hz : 1H) ; 7.43 (dd, J = 8 . 5 and 2 Hz : 1H)] . Example 6 20 By carrying out the operation according to the procedure of Example 1, but starting with 117 mg of 3-fluorophenylsulfonyl chloride, 13.5 mg of N-(1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-fluorophenyl-sulfonamide are obtained in the form of a 25 cream-colored lacquer [1H NMR spectrum (400 MHz, CDC13, 5 in ppm): 2.79 (split t, J = 7 and 2 Hz : 2H); 3.43 (split t, J = 7 and 2 Hz : 2H); 4.05 (unresolved complex : 1H); 4.24 (s : 1H); 4.91 (unresolved complex 29 : 1H); from 7.20 to 7.40 (mt : 9H); from 7.50 to 7.65 (mt : 2H) ; 7.67 (broad d, J = 8 Hz : 1H) ] . Example 7 By carrying out the operation according to 5 the procedure of Example 1, but starting with 147 mg of 3, 4-dichlorophenylsulfonyl chloride, 20 mg of N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3,4 -dichlorophenylsulfonamide are obtained in the form of a cream-colored lacquer [XH NMR spectrum (300 MHz, CDCI3, 10 5 in ppm): 2.77 (split t, J = 7 and 2 Hz : 2H); 3.40 (split t, J = 7 and 2 Hz : 2H); 3.98 (mt : 1H); 4.21 (s : 1H); from 4.85 to 5.15 (unresolved complex : 1H); from 7.20 to 7.35 (mt : 8H) ; 7.57 (d, J = 8.5 Hz : 1H) ; 7.65 (dd, J = 8.5 and 2 Hz : 1H); 7.93 (d, J = 2 Hz : 15 1H)] . Example 8 By carrying out the operation according to the procedure for Example 1, but starting with 121 mg of 3-cyanophenylsulfonyl chloride, 21 mg of 20 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3- cyanophenylsulfonamide are obtained in the form of a cream-colored lacquer [1H NMR spectrum (300 MHz, CDC13, 5 in ppm): 2.7 6 (split t, J = 7 and 2 Hz : 2H); 3.39 (split t, J = 7 and 2 Hz : 2H); 3.99 (mt : 1H); 4.21 25 (s : 1H); from 4.80 to 5.60 (very broad unresolved complex : 1H) ; from 7.15 to 7.35 (mt : 8H) ; 7.65 (t, J = 8 Hz : 1H); 7.86 (broad d, J = 8 Hz : 1H); 8.05 (broad d, J = 8 Hz : 1H) ; 8.13 (broad s : 1H) ] . 30 Example 9 By carrying out the operation according to the procedure of Example 1, but starting with 142 mg of 2,5-dimethoxyphenylsulfonyl chloride, 31 mg of 5 N-{1-[bis (4-chlorophenyl)methyl]azetidin-3-yl}- 2, 5-dimethoxyphenylsulfonamide are obtained in the form of a cream-colored lacquer [1H NMR spectrum (300 MHz, CDC13, 8 in ppm): 2.73 (split t, J = 7 and 2 Hz : 2H); 3.27 (split t, J = 7 and 2 Hz : 2H); 3.80 (s : 3H) ; 10 from 3.85 to 4.00 (mt : 1H); 3.94 (s : 3H) ; 4.19 (s : 1H); 5.32 (d, J = 8 Hz : 1H); 6.94 (d, J = 9 Hz : 1H); 7.05 (dd, J = 9 and 3 Hz : 1H); 7.23 (mt : 8H); 7.40 (d, J = 3 Hz : 1H)]. Example 10 15 By carrying out the operation according to the procedure of Example 1, but starting with 147 mg of 3-trifluoromethylphenylsulfonyl chloride, 8 mg of N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-trifluoromethylphenylsulfonamide are obtained in the 20 form of a cream-colored lacquer [1H NMR spectrum (300 MHz, CDCI3, 5 in ppm) : 2.79 (split t, J = 7 and 2 Hz : 2H); 3.41 (split t, J = 7 and 2 Hz : 2H); 4.03 (mt : 1H); 4.23 (s : 1H); from 4.80 to 5.10 (broad unresolved complex : 1H); from 7.20 to 7.35 (mt : 8H) ; 25 7.68 (t, J = 8 Hz : 1H); 7.87 (broad d, J = 8 Hz : 1H); 8.05 (broad d, J = 8 Hz : 1H); 8.15 (broad s : 1H)]. 31 Example 11 By carrying out the operation according to the procedure of Example 1, but starting with 136 mg of naphth-2-ylsulfonyl chloride, 20 mg of N-{l-[bis(4-5 chlorophenyl)methyl]azetidin-3-yl}naphth-2-yl- sulfonamide are obtained in the form of a cream-colored lacquer [1H NMR spectrum (400 MHz, CDCI3, 8 in ppm) : 2.74 (mt : 2H); 3.35 (mt : 2H); 4.02 (mt : 1H); 4.17 (s : 1H); 4.96 (unresolved complex : 1H); from 7.10 to 10 7.30 (mt : 8H); 7.64 (mt : 2H); 7.78 (dd, J = 7 and 1.5 Hz : 1H); 7.90 to 8.05 (mt : 3H); 8.41 (broad s : 1H) ] . Example 12 By carrying out the operation according to 15 the procedure of Example 1, but starting with 136 mg of naphth-l-ylsulfonyl chloride, 52 mg of N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}naphth-l-yl-sulfonamide are obtained in the form of a cream-colored foam [1H NMR spectrum (300 MHz, CDCI3, 8 in ppm) : 2.63 20 (split t, J = 7 and 2 Hz : 2H); 3.20 (split t, J = 7 and 2 Hz : 2H); 3.90 (mt : 1H); 4.12 (s : 1H) ; 5.26 (unresolved complex : 1H); 7.16 (mt : 8H); 7.52 (t, J = 8 Hz : 1H); from 7.55 to 7.75 (mt : 2H); 7.95 (d, J = 8.5 Hz : 1H); 8.06 (d, J = 8.5 Hz : 1H); 8.23 (dd, J = 25 7.5 and 1 Hz : 1H); 8.64 (d, J = 8.5 Hz : 1H)]. Example 13 By carrying out the operation according to the procedure of Example 1, but starting with 128 mg of 32 3,4-difluorophenylsulfonyl chloride, 7 mg of N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3,4 -difluorophenylsulfonamide are obtained in the form of a cream-colored lacquer [NMR spectrum (300 MHz, CDC13, 5 5 in ppm): 2.76 (broad t, J = 7.5 Hz : 2H); 3.39 (broad t, J = 7.5 Hz : 2H); 3.98 (mt : 1H); 4.20 (broad s : 1H); from 4.85 to 5.25 (broad unresolved complex : 1H); from 7.15 to 7.35 (mt : 9H); from 7.55 to 7.75 (mt : 2H) ] . 10 Example 14 By carrying out the operation according to the procedure of Example 1, but starting with 108 mg of l-methylimidazol-4-ylsulfonyl chloride, 22 mg of N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-l-15 methyl-l-H-imidazol-4-ylsulfonamide are obtained in the form of a cream-colored foam [1H NMR spectrum (300 MHz, CDCI3, with addition of a few drops of CD3COOD d4, § in ppm): 3.22 (mt : 2H); 3.67 (mt : 2H); 3.74 (s : 3H); 4.10 (mt : 1H); 4.65 (broad s : 1H); 7.27 (mt : 8H); 20 7.47 (broad d, J = 1 Hz : 1H); 7.53 (broad d, J = 1 Hz : 1H)]. Example 15 By carrying out the operation according to the procedure of Example 1, but starting with 152 mg of 25 4-acetamido-3-chlorophenylsulfonyl chloride, 69 mg of N-[4-(N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}sulfamoyl)-2-chlorophenyl]acetamide are obtained in the form of a cream-colored foam [1H NMR spectrum (300 33 MHz, CDCI3, 5 in ppm): 2.30 (s : 3H); 2.73 (mt : 2H); 3.38 (mt : 2H); 3.97 (mt : 1H); 4.19 (s : 1H); 7.24 (s : 8H); 7.70 (dd, J = 7 and 1.5 Hz : 1H); 7.78 (broad s : 1H); 7.86 (d, J = 1.5 Hz : 1H); 8.61 (d, J = 7 Hz : 5 1H)]. Example 16 0.7 9 cm3 of triethylamine is added, at room temperature under an argon atmosphere, to a solution of 0.7 g of 1-[bis(4-chlorophenyl)methyl]azetidin-3-10 ylamine in 25 cm3 of dichloromethane. The mixture is cooled to around 0°C before adding thereto a solution of 1.2 g of pyrid-3-ylsulfonyl chloride in 25 cm3 of dichloromethane, and then it is stirred at room temperature for 16 hours. The reaction mixture is 15 diluted with 50 cm3 of dichloromethane and is then washed with twice 25 cm3 of distilled water. The organic phase is dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure (2.7 kPa). The residue obtained is purified by flash 20 chromatography on silica gel [eluant: dichloromethane/methanol (97.5/2.5 by volume)]. 0.7 g of N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}pyrid-3-ylsulfonamide is obtained in the form of a cream-colored foam which solidifies in the presence of 25 isopropanol into a cream-colored powder melting at 164 °C. 34 Pyrid-3-ylsulfonyl chloride may be prepared according to the method described by Breant, P. et al., Synthesis, 10, 822-4 (1983). Example 17 5 0.214 g of 4-fluorophenylsulfonyl chloride and 0.28 cm3 of triethylamine are added, at room temperature under an argon atmosphere, to a solution of 0.307 g of 1-[bis(4-chlorophenyl)methyl]azetidin-3-ylamine in 10 cm3 of dichloromethane. After stirring for 10 16 hours at room temperature, the reaction mixture is washed with 10 cm3 of distilled water, dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure (2.7 kPa). The residue obtained is purified by flash chromatography on silica gel 15 [eluant: dichloromethane/ethyl acetate (100/0 to 95/5 by volume) gradient]. 0.18 g of N-{1-[bis(4-chlorophenyl ) methyl]azetidin-3-yl}-4-fluorophenylsulfonamide is obtained in the form of a white foam [1H NMR spectrum (300 MHz, CDC13, 5 in ppm) : 2.74 (broad t, J = 7.5 Hz : 20 2H); 2.39 (broad t, J = 7.5 Hz : 2H); 3.98 (mt : 1H); 4.20 (s : 1H); 4.79 (d, J = 9 Hz : 1H); from 7.10 to 7.35 (mt : 10H); 7.86 (mt : 2H)]. Example 18 By carrying out the operation according to 25 the procedure for Example 17, but starting with 0.25 g of quinol-8-ylsulfonyl chloride, 0.36 g of N-{l-[bis(4-chlorophenyl)methy1]azetidin-3-yl}quinol-8-ylsulfonamide is obtained in the form of a white powder [1H NMR 35 spectrum (300 MHz, CDCI3, 5 in ppm): 2.63 (split t, J = 7 and 2 Hz : 2H); 3.16 (split t, J = 7 and 2 Hz : 2H); 3.98 (mt : 1H); 4.11 (s : 1H); 6.77 (d, J = 8 Hz : 1H); 7.15 (mt : 8H) ; 7.61 (dd, J = 8 and 4 Hz : 1H) ; 7.64 5 (dd, J = 8 and 7.5 Hz) : 1H); 8.06 (dd, J = 8 and 1.5 Hz : 1H); 8.30 (dd, J = 8 and 1.5 Hz : 1H); 8.40 (dd, J = 7.5 and 1.5 Hz : 1H); 9.09 (dd, J = 4 and 1.5 Hz : 1H) ] . Example 19 10 By carrying out the operation according to the procedure of Example 17, but starting with 0.14 cm3 of phenylsulfonyl chloride, 0.35 g of N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}phenylsulfonamide is obtained in the form of a white powder [1H NMR spectrum 15 (300 MHz, CDCI3, 8 in ppm) : 2.75 (broad t, J = 7.5 Hz : 2H); 3.40 (broad t, J = 7.5 Hz : 2H); 4.03 (mt : 1H); 4.22 (s : 1H); 4.79 (d, J = 10 Hz : 1H); 7.31 (s : 8H); from 7.45 to 7.65 (mt : 3H); 7.87 (broad d, J = 7.5 Hz : 2H)]. 2 0 Example 20 By carrying out the operation according to the procedure of Example 17, but starting with 0.21 g of (phenylmethyl)sulfonyl chloride, 0.27 g of N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}(phenyl-25 methyl)sulfonamide is obtained in the form of a white powder [1H NMR spectrum (400 MHz, CDCI3, 8 in ppm) : 2.76 (split t, J = 7 and 2 Hz : 2H); 3.41 (split t, J = 7 and 2 Hz : 2H); 3.85 (mt : 1H); 4.20 (s : 1H); 4.23 (s 36 : 2H); 4.46 (d, J = 9 Hz : 1H); from 7.25 to 7.45 (mt : 13H)]. Example 21 By carrying out the operation according to 5 the procedure of Example 17, but starting with 0.42 g of 3,5-difluorophenylsulfonyl chloride in 30 cm3 of dichloromethane and washing the organic phase with twice 20 cm3 of distilled water. After purification by flash chromatography on silica gel [eluant: 10 dichloromethane/methanol (100/0 to 95/5 by volume) gradient], 0.1 g of N-{1-[bis(4-chlorophenyl)methyl]-azetidin-3-yl}-3,5-difluorophenylsulfonamide is obtained in the form of a yellow powder ["""H NMR spectrum (300 MHz, CDC13, 5 in ppm) : 2.77 (split t, J = 7 and 2 15 Hz : 2H); 3.41 (split t, J = 7 and 2 Hz : 2H); 4.01 (mt : 1H); 4.21 (s : 1H); 4.90 (d, J = 9 Hz : 1H); 7.02 (tt, J = 8.5 and 2.5 Hz : 1H); from 7.20 to 7.35 (mt : 8H); 7.38 (mt : 2H)]. 3,5-Difluorophenylsulfonyl chloride may be 20 prepared according to the method described in Patent FR 9615887. Example 22 By carrying out the operation according to the procedure of Example 21, but starting with 0.21 g 25 of pyrid-2-ylsulfonyl chloride and 0.17 cm3 of triethylamine and washing the organic phase with twice 30 cm3 of distilled water. After purification by flash chromatography on silica gel [eluant: 37 dichloromethane/methanol (100/0 to 98/2 by volume) gradient],0.3 g of N-{1-[bis(4-chlorophenyl)methyl]-azetidin-3-yl}pyrid-2-sulfonamide is obtained in the form of a white powder [1H NMR spectrum (300 MHz, CDCI3, 5 5 in ppm): 2.78 (split t, J = 7 and 2 Hz : 2H); 3.35 (split t, J = 7 and 2 Hz : 2H); 4.12 (mt : 1H); 4.20 (s: 1H); 5.30 (d, J = 9 Hz : 1H); from 7.15 to 7.35 (mt : 8H); 7.47 (ddd, J = 7.5 and 5 and 1 Hz : 1H); 7.90 (split t, J = 7.5 and 2 Hz; 1H); 7.98 (broad d, 10 J = 7.5 Hz : 1H); 8.65 (broad d, J = 5 Hz : 1H)]. Pyrid-2-ylsulfonyl chloride may be prepared according to the method described by Corey, E.J. et al., J. Org. Chem. (1989), 54(2), 389-93. Example 23 15 0.104 cm3 of pyrrolidine is added, at room temperature, to 0.24 g of N-{1-[bis(4-chlorophenyl)-methyl]azetidin-3-yl}-(3,5-difluorophenyl)sulfonamide in solution in 6 cm3 of dimethyl sulfoxide and then the mixture is heated for 18 hours at 90°C. The reaction 20 mixture is diluted with 30 cm3 of dichloromethane and washed with three times 30 cm3 of distilled water. The organic phased is dried over magnesium sulfate, filtered and concentrated to dryness under reduced pressure (2.7 kPa). The residue is purified by flash 25 chromatography on silica gel, eluting with dichloromethane. 50 mg of N-{1-[bis(4-chlorophenyl)-methyl]azetidin-3-yl}-(3-fluoro-5-pyrrolidin-1-ylphenyl)sulfonamide are thus obtained in the form of a 38 white powder [1H NMR spectrum (600 MHz, CDCI3 with addition of a few drops of CD3COOD d4, § in ppm) : 2.04 (mt : 4H); from 3.20 to 3.35 (mt : 6H); 3.60 (t, J = 8.5 Hz : 2H); 4.14 (mt : 1H); 4.57 (s : 1H); 6.31 5 (broad d, J = 11.5 Hz : 1H); 6.70 (broad d, J = 8.5 Hz : 1H); 6.72 (broad s : 1H); from 7.20 to 7.35 (mt : 8H)]. Example 24 A solution of 0.26 g of N-{1-[bis(4-chloro-10 phenyl)methyl]azetidin-3-yl}-4-fluorophenylsulfonamide in 5 cm3 of tetrahydrofuran is added, at room temperature under an argon atmosphere, to a suspension of 20.5 mg of 80% sodium hydride in 10 cm3 of tetrahydrofuran. After stirring for 1 hour at around 15 20°C, 60 mm3 of iodomethane are added and then after stirring for an additional 16 hours, the suspension is supplemented with 30 cm3 of ethyl acetate and 20 cm3 of distilled water. The organic phase is dried over magnesium sulfate, filtered and concentrated to dryness 20 under reduced pressure (2.7 kPa). The residue is purified by flash chromatography on silica gel [eluant: cyclohexane/ethyl acetate (90/10 by volume)]. 19 mg of N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-methyl-4-fluorophenylsulfonamide are thus obtained in 25 the form of a white powder [1H NMR spectrum (300 MHz, CDCI3, 8 in ppm): 2.69 (s : 3H); 3.02 (split t, J = 7 and 2 Hz : 2H); 3.35 (split t, J = 7 and 2 Hz : 2H); 39 3.91 (mt : 1H); 4.27 (s : 1H); from 7.15 to 7.35 (mt : 10H); 7.75 (dd, J = 9 and 5 Hz : 2H)]. Example 25 By carrying out the operation according to 5 the procedure of Example 24, but starting with 0.25 g of N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-quinol-8-ylsulfonamide and 18 mg of 80% sodium hydride. After purification by flash chromatography on silica gel [eluant: cyclohexane/ethyl acetate (80/20 by 10 volume)], 70 mg of N-{1-[bis (4-chlorophenyl)- methyl]azetidin-3-yl}-N-methylquinol-8-ylsulfonamide are obtained [1H NMR spectrum (300 MHz, CDCI3, 6 in ppm): from 3.00 to 3.10 (mt : 2H); 3.05 (s : 3H); 3.35 (mt : 2H); 4.27 (s : 1H); 4.93 (mt : 1H); from 7.15 to 15 7.35 (mt : 8H) ; 7.50 (dd, J = 8.5 and 4 Hz : 1H) ; 7.62 (dd, J = 8 and 8.5 Hz : 1H); 8.03 (dd, J = 8.5 and 1.5 Hz : 1H); 8.22 (dd, J = 8.5 and 1.5 Hz : 1H); 8.48 (dd, J = 8 and 1.5 Hz : 1H); 8.98 (dd, J = 4 and 1.5 Hz : 1H)]. 2 0 Example 26 By carrying out the operation according to the procedure of Example 24, but starting with 0.21 g of N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-phenylsulfonamide, 17 mg of 80% sodium hydride and 25 introducing iodomethane in two portions at an interval of 3 hours. 80 mg of N-{1-[bis(4-chlorophenyl)-methyl]azetidin-3-yl}-N-methylphenylsulfonamide are thus obtained in the form of a white lacquer [1H NMR 40 spectrum (300 MHz, CDCI3, 5 in ppm): 2.70 (s : 3H) ; 3.03 (broad t, J = 7.5 Hz : 2H); 3.37 (broad t, J = 7.5 Hz : 2H); 3.94 (mt : 1H); 4.28 (s : 1H); from 7.20 to 7.35 (mt : 8H); from 7.45 to 7.65 (mt : 3H); 7.74 (broad d, 5 J = 8 Hz : 2H)]. Example 27 By carrying out the operation according to the procedure of Example 26, but starting with 0.17 g of N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-10 (phenylmethyl)sulfonamide, 14 mg of 80% sodium hydride and maintaining stirred for 48 hours at 20°C. After purification by flash chromatography on silica gel [eluant: dichloromethane/ethyl acetate (95/5 by volume)], 120 mg of N-{1-[bis(4-chlorophenyl)-15 methyl]azetidin-3-yl}-N-methyl(phenylmethyl)sulfonamide are obtained in the form of a white foam [XH NMR spectrum (300 MHz, CDCI3, 5 in ppm): 2.81 (s : 3H); 2.88 (split t, J = 7 and 2 Hz : 2H); 3.16 (split t, J = 7 and 2 Hz : 2H); from 4.10 to 4.25 (mt : 4H); from 7.20 20 to 7.40 (mt : 13H)]. Example 28 A solution of 0.307 g of 1-[bis(4-chlorophenyl) methyl]azetidin-3-ylamine is added dropwise, at room temperature, to a solution of 0.412 g of 25 1,3-benzenedisulfonic acid dichloride and 0.165 cm3 of triethylamine in 10 cm3 of acetonitrile. After stirring for 3 hours at room temperature, 0.28 cm of a 20% solution of ammonia is added and the reaction mixture is left at room temperature. After 18 hours, the mixture is filtered and concentrated to dryness under reduced pressure (2.7 kPa). After chromatography on a silica gel column (particle size 0.06-0.200 mm, height 5 35 cm, diameter 2 cm), eluting under an argon pressure of 0.9 bar with dichloromethane and then a mixture of dichloromethane + 1% methanol and then a mixture of dichloromethane + 2% methanol by volume and collecting 30-cm3 fractions, fractions 23 to 34 are combined and 10 concentrated to dryness under reduced pressure (2.7 kPa) to give 90 mg of N-{1-[bis(4-chlorophenyl)-methyl]azetidin-3-yl}-3-sulfamoylphenylsulfonamide in the form of a white solid [1H NMR spectrum (300 MHz, CDC13, 5 in ppm): 2.78 (broad t, J = 7 Hz : 2H); 3.35 15 (broad t, J = 7 Hz : 2H); 4.01 (mt : 1H); 4.24 (s : 1H); 5.27 (unresolved complex : 2H); 5.61 (unresolved complex : 1H); from 7.15 to 7.35 (mt : 8H) ; 7.67 (t, J = 8 Hz : 1H); 8.04 (broad d, J = 8 Hz : 1H); 8.12 (broad d, J = 8 Hz : 1H); 8.49 (broad s : 1H)]. 2 0 Example 29 0.031 cm3 of diisopropylcarbodiimide, a solution of 30 mg of 1-[bis(4-chlorophenyl)-methyl]azetidin-3-ylamine in 0.5 cm3 of anhydrous dichloromethane, and 3 cm3 of anhydrous dichloromethane 25 are added to a solution of 80.1 mg of benzenesulfonylacetic acid, 27 mg of hydroxybenzotriazole in solution in 0.5 cm3 of dimethylformamide under an inert argon atmosphere, at a 42 temperature in the region of 23°C. After 17 hours at a temperature in the region of 23°C, the reaction mixture is loaded onto a 3-cm3 SPE cartridge containing 1 g of SCX phase preconditioned with methanol. After washing 5 with twice 5 cm3 of methanol and then 4 cm3 of 0.1 N ammoniacal methanol, the expected product is eluted with 4 cm3 of 1 N ammoniacal methanol. The fraction containing the expected product is evaporated under an air stream at a temperature in the region of 45°C and 10 then dried under reduced pressure (1 mbar) at a temperature in the region of 40°C. 2-Benzenesulfonyl-N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}acetamide is thus obtained in the form of a white solid [1H NMR spectrum (500 MHz, CDCI3, 8 in ppm): 2.96 (mt : 2H); 15 3.51 (mt : 2H); 4.00 (s : 2H); 4.34 (unresolved complex : 1H); 4.48 (mt : 1H); 7.10 (unresolved complex : 1H); from 7.20 to 7.45 (mt : 8H); 7.57 (t, J = 8 Hz : 2H); 7.70 (t, J = 8 Hz : 1H); 7.90 (d, J = 8 Hz : 2H)]. Example 30 20 0.031 cm3 of diisopropylcarbodiimide, a solution of 30 mg of 1-[bis (4-chlorophenyl)-methyl]azetidin-3-ylamine in 0.5 cm3 of anhydrous dichloromethane, and 3 cm3 of anhydrous dichloromethane are added to a solution of 85.7 mg of 25 toluenesulfonylacetic acid, 27 mg of hydroxybenzotriazole in solution in 0.5 cm of dimethylformamide under an inert argon atmosphere, at a temperature in the region of 23°C. After 17 hours at a 43 temperature in the region of 23°C, the reaction mixture is loaded onto a 3-cm3 SPE cartridge containing 1 g of SCX phase preconditioned with methanol. After washing with twice 5 cm3 of methanol and then 4 cm3 of 0.1 N 5 ammoniacal methanol, the expected product is eluted with 4 cm3 of 1 N ammoniacal methanol. The fraction containing the expected product is evaporated under an air stream at a temperature in the region of 45°C and then dried under reduced pressure (1 mbar) at a 10 temperature in the region of 40°C. N-{l-[bis(4-chlorophenyl)methyl]-azetidin-3-yl}-2-(toluene-4-sulfonyl)acetamide is obtained in the form of a yellow lacquer [XH NMR spectrum (500 MHz, CDC13, 5 in ppm) : 2.85 (t, J = 7 Hz : 2H); 3.07 (s : 3H); 3.48 (t, J = 7 15 Hz : 2H); 4.24 (s : 1H); 4.49 (mt : 1H); 7.19 (broad d, J = 6 Hz : 1H); from 7.2 0 to 7.40 (mt : 8H); 8.4 0 (s : 1H) ] . Example 31 By carrying out the operation according to 20 the procedure of Example 30, starting with 85.7 mg of 3-chloro-4-methylsulfonythiophene-2-carboxylie acid, 27 mg of hydroxybenzotriazole in solution in 0.5 cm3 of dimethylformamide, 0.031 cm3 of diisopropylcarbodiimide, a solution of 30 mg of 1-[bis(4-chlorophenyl)methyl]-25 azetidin-3-ylamine in 0.5 cm3 of anhydrous dichloromethane, and 3 cm3 of anhydrous dichloromethane, (3-chloro-4-methylsulfonylthiophene-2-carboxy)-{1-bis(4-chlorophenyl)methyl]azetidin-3-yl}amide is 44 obtained in the form of a yellow lacquer [1H NMR spectrum (500 MHz, CDCI3, 5 in ppm): 2.44 (s : 3H); 2.96 (unresolved complex : 2H); 3.52 (unresolved complex : 2H) ; 3.98 (s : 2H) ; 4.35 (unresolved complex : 1H) ; 5 4.49 (mt : 1H); from 7.00 to 7.30 (broad unresolved complex : 1H); from 7.20 to 7.45 (mt : 10H); 7.7 6 (d, J = 8 Hz : 2H) ] . Example 32 By carrying out the operation according to 10 the procedure of Example 30, starting with 96.1 mg of 3-(2-phenylethylenesulfonyl)propionic acid, 27 mg of hydroxybenzotriazole in solution in 0.5 cm3 of dimethylformamide, 0.031 cm3 of diisopropylcarbodiimide, a solution of 30 mg of 1-[bis(4-chlorophenyl)methyl]-15 azetidin-3-ylamine in 0.5 cm3 of anhydrous dichloromethane, and 3 cm3 of anhydrous dichloromethane, N-[1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-(2-phenylethylenesulfonyl)propionamide is obtained in the form of a white foam [1H NMR spectrum (500 MHz, CDCI3, 6 20 in ppm): 2.64 (t, J = 7 Hz : 2H); 2.88 (unresolved complex : 2H); 3.33 (t, J = 7 Hz : 2H); 3.49 (unresolved complex : 2H); 4.29 (unresolved complex : 1H); 4.48 (mt : 1H); from 5.90 to 6.15 (broad unresolved complex : 1H); 6.41 (d, J = 12 Hz : 1H); 25 7.17 (d, J = 12 Hz : 1H); from 7.20 to 7.35 (mt : 8H); 7.41 (mt : 3H); 7.64 (mt : 2H)]. Example 33 45 By carrying out the operation according to the procedure of Example 31, starting with 58.5 mg of 4-methylsulfonylbenzoic acid, 26.4 mg of hydroxybenzotriazole in solution in 0.5 cm3 of 5 dimethylformamide, 0.0302 cm3 of diisopropyl-carbodiimide, a solution of 30 mg of l-[bis(4-chlorophenyl)methyl]azetidin-3-ylamine in 0.5 cm3 of anhydrous dichloromethane, and 3 cm3 of anhydrous dichloromethane, N-{1-[bis (4-chlorophenyl)-10 methyl]azetidin-3-yl}-4-methylsulfonylbenzamide is obtained in the form of a white crystals [1H NMR spectrum (300 MHz, CDCI3, 5 in ppm) : 3.03 (mt : 2H) ; 3.09 (s : 3H) ; 3.61 (broad t, J = 7.5 Hz : 2H) ; 4.35 (s : 1H); 4.73 (mt : 1H); 6.55 (broad d, J = 7.5 Hz : 1H); 15 from 7.20 to 7.35 (mt : 8H) ; 7.96 (d, J = 8 Hz : 2 H) ; 8.03 (d, J = 8 Hz : 2H)]. Example 34 By carrying out the operation according to the procedure of Example 31, starting with 58.5 mg of 20 3-phenylsulfonylpropionic acid, 26.4 mg of hydroxybenzotriazole in solution in 0.5 cm3 of dimethylformamide, 0.0302 cm3 of diisopropyl-carbodiimide, a solution of 30 mg of l-[bis(4-chlorophenyl)methyl]azetidin-3-ylamine in 0.5 cm3 of 25 anhydrous dichloromethane, and 3 cm3 of anhydrous dichloromethane, N-{1-[bis(4-chlorophenyl)-methyl]azetidin-3-yl}-4-methanesulfonylbenzamide is obtained in the form of a lacquer [1H NMR spectrum 46 (300 MHz, CDCI3, 5 in ppm): 2.71 (t, J = 7.5 Hz : 2 H) ; 2.86 (mt : 2H); from 3.40 to 3.55 (mt : 4H); 4.26 (s : 1H); 4.45 (mt : 1H); 6.22 (broad d, J = 7.5 Hz : 1H); from 7.20 to 7.35 (mt : 8H); 7.59 (broad t, J = 7.5 Hz 5 : 2H); 7.69 (tt, J = 7.5 and 1.5 Hz : 1H); 7.93 (broad d, J = 7.5 Hz : 2H)] . Example 35 By carrying out the operation according to the procedure of Example 31, starting with 60.2 mg of 10 5-methylsulfonylthiophene-2-carboxylic acid, 26.4 mg of hydroxybenzotriazole in solution in 0.5 cm3 of dimethylformamide, 0.0302 cm3 of diisopropyl-carbodiimide, a solution of 30 mg of l-[bis(4-chlorophenyl)methyl]azetidin-3-ylamine in 0.5 cm3 of 15 anhydrous dichloromethane, and 3 cm3 of anhydrous dichloromethane, (5-methylsulfonylthiophene-2-carboxy)-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}amide is obtained in the form of white crystals [1H NMR spectrum (300 MHz, CDCI3, 5 in ppm): 3.03 (mt : 2H); 3.21 (s : 20 3H) ; 3.57 (dd, J = 8 and 7.5 Hz : 2H) ; 4.34 (s : 1H) ; 4.67 (mt : 1H); 6.40 (broad d, J = 7.5 Hz : 1H); from 7.20 to 7.35 (mt : 8H); 7.48 (d, J = 4 Hz : 1H); 7.67 (d, J = 4 Hz : 1H)]. Example 36 25 By carrying out the operation according to the procedure of Example 31, starting with 71.9 mg of 5-methylsulfonyl-3-methyl-4-vinylthiophene-2-carboxylic acid, 26.4 mg of hydroxybenzotriazole in solution in Al 0.5 cm3 of dimethylformamide, 0.0302 cm3 of diisopropylcarbodiimide, a solution of 30 mg of 1-[bis(4-chlorophenyl)methyl]azetidin-3-ylamine in 0.5 cm3 of anhydrous dichloromethane, and 3 cm3 of 5 anhydrous dichloromethane, (5-methylsulfonyl-3-methyl-4-vinylthiophene-2-carboxy){1-[bis-(4-chlorophenyl)-methyl]azetidin-3-yl}amide is obtained in the form of a white powder [1H NMR spectrum (300 MHz, CDCI3, 5 in ppm): 2.47 (s : 3H); 2.97 (mt : 2H); 3.14 (s : 3H); 10 3.57 (dd, J = 8 and 7.5 Hz : 2H); 4.32 (s : 1H); 4.65 (mt : 1H) ; 5.6 9 (dd, J = 18 and 1 Hz : 1H) ; 5.7 7 (dd, J = 12 and 1 Hz : 1H); 6.30 (broad d, J = 7.5 Hz : 1H); 6.96 (dd, J = 18 and 12 Hz : 1H); from 7.20 to 7.35 (mt : 8H)]. 15 Example 37 By carrying out the operation according to the procedure of Example 31, starting with 62.6 mg of 3-methylsulfonylmethylbenzoic acid, 26.4 mg of hydroxybenzotriazole in solution in 0.5 cm3 of 20 dimethylformamide, 0.0302 cm3 of diisopropylcarbodiimide, a solution of 30 mg of l-[bis(4-chlorophenyl)methyl]azetidin-3-ylamine in 0.5 cm3 of anhydrous dichloromethane, and 3 cm3 of anhydrous dichloromethane, (5-methylsulfonyl-3-methy1-4-25 vinylthiophene-2-carboxy){1-[bis(4-chlorophenyl)- methyl]azetidin-3-yl}amide is obtained in the form of white needles [1H NMR spectrum (300 MHz, (CD3)2SO d6 with addition of CDC13, 5 in ppm): 2.84 (s : 3H); 3.02 48 (broad t, J = 7 Hz : 2H); 3.48 (t, J = 7 Hz : 2H); 4.38 (s : 3H); 4.53 (mt : 1H); 7.21 (d, J = 8 Hz : 4H); 7.34 (d, J = 8 Hz : 4H); 7.40 (t, J = 7.5 Hz : 1H); 7.53 (broad d, J = 7.5 Hz : 1H); 7.84 (broad d, J = 7.5 Hz : 5 1H); 7.89 (broad s : 1H); 8.54 (d, J = 7 Hz : 1H)]. Example 38 (RS)-N-{1-[(4-chlorophenyl)pyridin-3-ylmethyl] azetidin-3-yl)-3,5-difluorobenzenesulfonamide may be obtained in the following manner: 0.46 g of 10 potassium carbonate and 41 mg of potassium iodide are added to a mixture of 0.3 g of (RS)-3-[bromo-(4-chlorophenyl)methyl]pyridine hydrobromide and 0.28 g of N-azetidin-3-yl-3,5-difluorobenzenesulfonamide hydrochloride in 2 0 cm3 of acetonitrile, and then the 15 mixture is heated under reflux for 4 hours. After cooling to a temperature in the region of 2 0°C, the insoluble matter is removed by filtration and then the mixture is concentrated to dryness under reduced pressure. The residue obtained is taken up in 100 cm3 of 2 0 ethyl acetate. The organic phase is washed with twice 50 cm3 of water, dried over magnesium sulfate in the presence of animal charcoal, filtered on Celite, and then concentrated to dryness under reduced pressure. 23 0 mg of an orange-colored solid are obtained, which 25 solid is dissolved in a eyelohexane-ethyl acetate mixture (50-50 by volume mixture) and purified by chromatography under pressure on a cartridge of 10 g of silica with the same eluent mixture, with a flow rate 49 of 6 cm3/minute. Fractions 22 to 56 are combined and concentrated to dryness under reduced pressure. 100 mg of (RS)-N-{1-[(4-chlorophenyl)pyridin-3-ylmethyl ]azetidin-3-yl}-3,5-difluorobenzenesulfonamide 5 are thus obtained in the form of a pale yellow foam melting at 70°C [1H NMR spectrum (300 MHz, CDCI3, 5 in ppm): 2.81 (mt : 2H); 3.42 (mt : 2H); 4.03 (mt : 1H); 4.29 (s : 1H) ; 5.43 (d, J = 9 Hz : 1H) ; 7.01 (tt, J = 9 and 2.5 Hz : 1H); 7.22 (dd, J = 8 and 5 Hz : 1H); 7.2 8 10 (mt : 4H); 7.3 6 (mt : 2H); 7.62 (broad d, J = 8 Hz : 1H); 8.48 (dd, J = 5 and 1 Hz : 1H); 8.59 (d, J = 1 Hz : 1H)]. (RS)-3 -[bromo-(4-chlorophenyl)methyl]pyridine is obtained in the following manner: 3.5 cm3 of a 48% 15 hydrobromic acid solution in acetic acid and 1 cm3 of acetyl bromide are added to 1.5 g of (4-chlorophenyl)-pyridin-3-ylmethanol. The amber-colored mixture thus obtained is heated under reflux for 4 hours and then cooled to 20 °C, and concentrated to dryness at 40°C 20 under 2.7 kPa, giving 1.53 g of (RS)-3-[bromo-(4-chlorophenyl)methyl]pyridine (Rf = 75/90, 254 nm, silica plates, reference 1.05719, Merck KGaA, 64271 Darmstadt, Germany). N-azetidin-3-yl-3,5-difluorobenzene-2 5 sulfonamide hydrochloride may be prepared in the following manner: in a 2000 cm3 hydrogenator, a solution of 7.5 g of N-(l-benzhydrylazetidin-3-yl)-3,5- difluorobenzenesulfonamide in a mixture of 10 cm3 of 50 concentrated hydrochloric acid (3 6% by weight), 1.7 cm3 of acetic acid and 500 cm3 of methanol is hydrogenated in the presence of 4.21 g of palladium hydroxide on carbon (2 0% by weight of catalyst) under 1.7 bar of 5 hydrogen for about 2 0 hours. The catalyst is removed by filtration on a bed of Celite and then the filtrate is concentrated to dryness under reduced pressure. The residue obtained is beaten with 100 cm3 of diisopropyl ether for about 16 hours at a temperature in the region 10 of 20°C. The suspension is filtered, and the solid residue is again beaten with 100 cm3 of diethyl ether at a temperature in the region of 20°C. After filtration, the paste obtained is dried under reduced pressure at a temperature in the region of 40°C. 5.52 g of 15 N-azetidin-3-yl-3,5-difluorobenzenesulfonamide hydrochloride are thus obtained in the form of a white powder. N-(l-benzhydrylazetidin-3-yl)-3,5-difluorobenzenesulfonamide may be prepared in the 20 following manner: 5.1 g of 3,5-difluorobenzenesulfonyl chloride and then 4.2 cm3 of triethylamine are successively added to a suspension of 5 g of l-benzhydrylazetidin-3-ylamine in 80 cm3 of dichloromethane, at a temperature in the region of 2 5 2 0°C. After stirring for 20 hours at a temperature in the region of 2 0°C, 50 cm3 of water are added. The organic phase separated after settling is washed with twice 50 cm3 of water, dried over magnesium sulfate, and 51 concentrated to dryness under reduced pressure. 8.99 g of a yellow oil are thus obtained, which oil crystallizes little by little. 4.5 g of this product is purified by chromatography under pressure on 5 00 g of 5 Amicon silica (diameter of the particles from 0.020 to 0.045 mm), eluting with a methanol-dichloromethane (1-99 by volume) mixture. The fractions containing the desired product are combined and concentrated to dryness under reduced pressure to give 3.58 g of 10 N-(l-benzhydrylazetidin-3-yl)-3,5-difluorobenzenesulf onamide in the form of a beige powder. The remaining quantity of the preceding yellow oil is purified under the same conditions and provides 3.92 g of N-(l-benzhydrylazetidin-3-yl)-3,5-difluorobenzene-15 sulfonamide in the form of a beige powder. l-Benzhydrylazetidin-3-ylamine may be prepared as described in J. Antibiot., 39(9), 1243-1256, 1986. 3,5-Difluorobenzenesulfonyl chloride may be 20 prepared as described in patent: FR2757509. Example 39 (RS)-N-{1-[(4-chlorophenyl)pyrimidin-5-yl-methyl]azetidin-3-yl}-3,5-difluorobenzenesulfonamide may be obtained by carrying out the procedure as for 25 the preparation of (RS)-N-{1-[(4-chlorophenyl)pyridin-3-ylmethyl]azetidin-3-yl}-3,5-difluorobenzene-sulfonamide: starting with 0.64 g of (RS)-5-[bromo-(4-chlorophenyl)methyl]pyrimidine hydrobromide, 0.5 g 52 of N-azetidin-3-yl-3,5-difluorobenzenesulfonamide hydrochloride in 20 cm3 of acetonitril, 1.213 g of potassium carbonate and 3 79 mg of potassium iodide, 71 mg of (RS)-N-{1-[(4-chlorophenyl)pyrimidin-5-yl-5 methyl]azetidin-3-yl}-3,5-difluorobenzenesulfonamide are thus obtained in the form of a yellow foam [1H NMR spectrum (300 MHz, CDC13, 8 in ppm): 2.83 (mt : 2H) ; 3.46 (mt : 2H); 4.03 (mt : 1H); 4.30 (s : 1H); 5.00 (d, J = 9 Hz : 1H); 7.04 (tt, J = 9 and 2.5 Hz : 1H); from 10 7.20 to 7.35 (mt : 4H); 7.37 (mt : 2H); 8.69 (s : 2H); 9.09 (s : 1H)]. (RS)-5-[bromo-(4-chlorophenyl)methyl]-pyrimidine may be prepared by carrying out the procedure as for the preparation of (RS)-3-[bromo-(4-15 chlorophenyl)methyl]pyridine using, as raw material, (4-chlorophenyl)pyrimidin-5-ylmethanol. (4-Chlorophenyl)pyrimidin-5-ylmethanol may be prepared by carrying out the procedure as for (4-chlorophenyl)pyridin-3-ylmethanol, starting with 20 pyrimidine-5-carboxaldehyde and 4-chlorophenylmagnesium bromide. The medicaments according to the invention consist of a compound of formula (I) or an isomer or a salt of such a compound, in the pure state or in the 25 form of a composition in which it is combined with any other pharmaceutically compatible product which may be inert or physiologically active. The medicaments 53 according to the invention may be used orally, parenterally, rectally or topically. As solid compositions for oral administration, tablets, pills, powders (gelatin 5 capsules, sachets) or granules may be used. In these compositions, the active ingredient according to the invention is mixed with one or more inert diluents, such as starch, cellulose, sucrose, lactose or silica, under an argon stream. These compositions may also 10 comprise substances other than diluents, for example one or more lubricants such as magnesium stearate or talc, a coloring, a coating (sugar-coated tablets) or a glaze. As liquid compositions for oral 15 administration, there may be used pharmaceutically acceptable solutions, suspensions, emulsions, syrups and elixirs containing inert diluents such as water, ethanol, glycerol, vegetable oils or paraffin oil. These compositions may comprise substances other than 20 diluents, for example wetting, sweetening, thickening, flavoring or stabilizing products. Sterile compositions for parenteral administration may be preferably solutions which are aqueous or nonaqueous, suspensions or emulsions. As 2 5 solvent or vehicle, there may be used water, propylene glycol, polyethylene glycol, vegetable oils, in particular olive oil, injectable organic esters, for example ethyl oleate or other suitable organic 54 solvents. These compositions may also contain adjuvants, in particular wetting, isotonizing, emulsifying, dispersing and stabilizing agents. Sterilization may be carried out in several ways, for 5 example by asepticizing filtration, by incorporating sterilizing agents into the composition, by irradiation or by heating. They may also be prepared in the form of sterile solid compositions which may be dissolved at the time of use in sterile water or any other 10 injectable sterile medium. Compositions for rectal administration are suppositories or rectal capsules which contain, in addition to the active product, excipients such as cocoa butter, semisynthetic glycerides or polyethylene 15 glycols. Compositions for topical administration may be, for example, creams, lotions, collyria, collutoria, nasal drops or aerosols. In human therapy, the compounds according to 20 the invention are particularly useful for the treatment and/or prevention of psychoses including schizophrenia, anxiety disorders, depression, epilepsy, neurodegeneration, cerebellar and spinocerebellar disorders, cognitive disorders, cranial trauma, panic 2 5 attacks, peripheral neuropathies, glaucomas, migraine, Parkinson's disease, Alzheimer's disease, Huntington's chorea, Raynaud's syndrome, tremor, obsessive-compulsive disorder, senile dementia, thymic disorders, 55 Tourette's syndrome, tardive dyskinesia, bipolar disorders, cancers, movement disorders induced by medicaments, dystonia, endotoxemic shocks, hemorrhagic shocks, hypotension, insomnia, immunological diseases, 5 multiple sclerosis, vomiting, asthma, appetite disorders (bulimia, anorexia), obesity, memory disorders, intestinal transit disorders, in weaning from chronic treatments and alcohol or drug abuse (opioids, barbiturates, cannabis, cocaine, amphetamine, 10 phencyclide, hallucinogens, benzodiazepines for example), as analgesics or potentiators of the analgesic activity of the narcotic and nonnarcotic drugs. The doses depend on the desired effect, the 15 duration of the treatment and the route of administration used; they are generally between 5 mg and 1000 mg per day orally for an adult with unit doses ranging from 1 mg to 250 mg of active substance. In general, the doctor will determine the 20 appropriate dosage depending on the age, weight and any other factors specific to the subject to be treated. The following examples illustrate the compositions according to the invention: 25 EXAMPLE A Gelatin capsules containing a dose of 50 mg of active product and having the following composition are prepared according to the usual technique: 56 - Compound of formula (I) 50 mg - Cellulose 18 mg - Lactose 55 mg - Colloidal silica 1 mg 5 - Sodium carboxymethylstarch 10 mg - Talc 10 mg - Magnesium stearate 1 mg EXAMPLE B 10 Tablets containing a dose of 50 mg of active product and having the following composition are prepared according to the usual technique: - Compound of formula (I) 50 mg - Lactose 104 mg 15 - Cellulose 40 mg - Polyvidone 10 mg - Sodium carboxymethylstarch 22 mg - Talc 10 mg - Magnesium stearate 2 mg 20 - Colloidal silica 2 mg - Mixture of hydroxymethyIcellulose, glycerin, titanium oxide (72-3.5-24.5) qs 1 finished film-coated tablet containing 245 mg 25 EXAMPLE C An injectable solution containing 10 mg of active product and having the following composition is prepared: </div>

Claims

<div class="application article clearfix printTableText" id="claims"> 57 Compound of formula (I) 10 mg Benzoic acid 80 mg Benzyl alcohol 0.06 ml Sodium benzoate 80 mg Ethanol, 95% 0.4 ml Sodium hydroxide 24 mg Propylene glycol 1. 6 ml Water qs 4 ml 58 CLAIMS

1. Pharmaceutical composition containing, 5 as active ingredient, a compound of formula: R, n- (I) in which 10 Ri represents a radical -NHCOR4 or -N(R5)-Y-RS, Y is S02, R2 and R3, which are identical or different, represent either phenyl which is substituted with one or more halogen atoms; or a heteroaromatic chosen from 15 pyrimidinyl and pyridyl; R4 represents a radical -alk-S02-Rn, -alk-S02-CH=CH-Rn, Het substituted with -S02-Rn or phenyl substituted with -S02-Rh or -alk-S02-Rn, R5 represents a hydrogen atom or an alkyl radical, 2 0 R6 represents a phenylalkyl, Het or Ar radical, Ru represents an alkyl, Ar or Het radical, Ar represents a phenyl or naphthyl radical, these radicals being optionally substituted with one or more halogen atoms or alkyl, alkoxy, cyano, CF3, -S02NH2, intellectual property office of n.z. - 9 jun 2004 RFCEIVEn 59 -NH-COCH3 or Het radicals, or alternatively Het represents a 3- to 10-membered unsaturated or saturated mono- or bicyclic heterocycle containing one or more heteroatoms chosen from oxygen, sulfur and nitrogen 5 optionally substituted with one or more halogen atoms or alkyl or vinyl radicals, alk represents an alkyl or alkylene radical, the alkyl and alkylene radicals and portions and the alkoxy radicals and portions are in the form of a 10 straight or branched chain and contain 1 to 6 carbon atoms, an optical isomer of such a compound or one of its pharmaceutically acceptable salts.

2. A composition according to claim 1 15 wherein in the compound of formula (I) Het is chosen from thiophene, quinoline, pyridine, imidazole and pyrrolidine, these heterocycles being optionally substituted with one or more halogen atoms or alkyl radicals. 20 3. A composition according to claim 1 in which Ri represents a radical -N(R5)-Y-R6, Y, R2, R

3, R4, R5, Re/ Ar and alk are as defined in claim 1; and 25 Het is chosen from thiophene, quinoline, pyridine and pyrrolidine, these heterocycles being optionally substituted with one or more halogen atoms or alkyl or vinyl radicals, INTELLECTUAL PROPERTY OFFICE OF N.Z. - 9 jun 2004 ncPCIUCn 60 an optical isomer of such a compound or one of its pharmaceutically acceptable salts. in which Ri represents a radical -NHC0R4 or -N(R5)-Y-R6, 10 Y is S02, R2 and R3, which are identical or different, represent either a phenyl which is substituted with one or more halogen atoms, or a heteroaromatic chosen from pyrimidinyl and pyridyl, 15 R4 represents a radical -alk-S02-Rn, -alk-S02-CH=CH-Rll7 Het substituted with -S02-Rn or phenyl substituted with -S02~Rii or _alk-S02-Rh, R5 represents a hydrogen atom or an alkyl radical, R6 represents a phenylalkyl, Het or Ar radical, 2 0 Rn represents an alkyl, Ar or Het radical, Ar represents a phenyl or naphthyl radical, these radicals being optionally substituted with one or more halogen atoms or alkyl, alkoxy, cyano, CF3, -S02NH2, -NH-COCH3 or Het radicals, or alternatively,

4. A Compound of formula: 5 (I) INTELLECTUAL PROPERTY OFFICE OF N7. - 9 jun 2004 p 1 if p n 61 Het represents a 3- to 10-membered unsaturated or saturated mono- or bicyclic heterocycle containing one or more heteroatoms chosen from oxygen, sulfur and nitrogen optionally substituted with one or more 5 halogen atoms or alkyl or vinyl radicals; alk represents an alkyl or alkylene radical, the alkyl and alkylene radicals and portions and the alkoxy radicals and portions are in the form of a straight or branched chain and contain 1 to 6 carbon 10 atoms, an optical isomer of such a compound or one of its pharmaceutically acceptable salts, with the exception of the compound for which for which R2 and R3 represent phenyl radicals, Ri represents a 15 radical -N(R5)-Y-R6, Y is S02, R5 represents a methyl radical and Rs represents a phenyl radical.

5. A compound according to claim 4 wherein Het is chosen from thiophene, quinoline, pyridine, imidazole, and pyrrolidine, these heterocycles being 20 optionally substituted with one or more halogen atoms or alkyl.

6. A compound according to claim 4 in which Ri represents a radical -N(R5)-Y-R6, Y, R2, R3, R5, R6/ Rh and Ar are as defined in claim 4, 25 and Het is chosen from thiophene, quinoline, pyridine, imidazole and pyrrolidine, these heterocycles being INTELLECTUAL PROPERTY OFFICE OF N.Z. - 9 JUN 2004 62 optionally substituted with one or more halogen atoms or alkyl radicals, their optical isomers and their pharmaceutically acceptable salts, with the exception of the compound in which R2 and R3 represent phenyl radicals, Ri represents a radical -N(R5)-Y-R6, Y is S02, R5 represents a methyl radical and R6 represents a phenyl radical.

7. N-{1-[bis(4-chlorophenyl)-methyl]azetidin-3-yl}thien-2-ylsulfonamide N-{1- [bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-methoxyphenylsulfonamide N-[4-(N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}sulfamoyl)phenyl]acetamide N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-4-methylphenyl-sulfonamide N-{1- [bis(4-chlorophenyl)methyl]azetidin-3-yl}-3,4-dimethoxyphenylsulfonamide N-{1- [bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-fluorophenyl-sulfonamide N-{1- [bis(4-chlorophenyl)methyl]azetidin-3-yl}-3,4-dichlorophenylsulfonamide N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-cyanopheny1sulfonamide N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-2,5-dimethoxyphenylsulfonamide N-{l- [bis(4-chlorophenyl)methyl]azetidin-3-yl}-3-trifluoromethylsulfonamide INTELLECTUAL PROPERTY OFFICE OF N.Z. - 9 jun 2004 ■tppciucn 63 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}naphth-2-yl-sulfonamide N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}naphth-l-yl-sulfonamide 5 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3,4 -difluorophenylsulfonamide N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-1-methyl-l-H-imidazol-4-ylsulfonamide N-[4-(N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-10 yl}sulfamoyl)-2-chlorophenyl]acetamide N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}pyrid-3-ylsulfonamide N-{1-[bis(4-chloro-phenyl)methyl]azetidin-3-yl}-4-fluorophenylsulfonamide 15 N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}quinol-8 -ylsulfon-amide N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}phenylsulfonamide N-{l-[bis(4-chlorophenyl)methyl] azetidin-3-yl}(phenyl-2 0 methyl)sulfonamide N-{1-[bis(4-chlorophenyl)methyl]-azetidin-3-yl}-3,5-di fluorophenylsulfonamide N-{l-[bis(4-chlorophenyl)methyl]-azetidin-3-yl}pyrid-2-sulfonamide 25 N-{1-[bis(4-chlorophenyl)-methyl] azetidin-3-yl}- (3-fluoro-5-pyrrolidin-1-ylpheny1)sulfonamide N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-methyl-4 -fluorophenylsulfonamide INTELLECTUAL PROPERTY OFFICE OF N.Z. - 9 JUN 2004 64 20 N- {1- [bis (4-chlorophenyl) -methyl] azetidin-3 -yl} -time thy 1 quinol -8-ylsulfonamide N-{1-[bis(4-chlorophenyl)-methyl]azetidin-3-yl}-N-methylphenylsulfonamide N-{1-[bis(4-chlorophenyl)-methyl]azetidin-3-yl}-N-methyl(phenylmethyl)sulfonamide N-{l-[bis(4-chlorophenyl)-methyl]azetidin-3-yl}-3 -sulfamoylphenylsulfonamide 2-Benzenesulfonyl-N-{l-[bis(4-chlorophenyl)methyl]azetidin-3-yl}acetamide N-{1-[bis(4-chlorophenyl)methyl]-azetidin-3-yl}-2-(toluene-4-sulfonyl)acetamide (3-chloro-4-methylsulfonylthiophene-2-carboxy)-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}amide N- {1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-3 -(2 -phenylethylenesulfonyl)propionamide N-{l- [bis(4-chlorophenyl)-methyl]azetidin-3-yl}-4-methylsulfonylbenzamide N-{1- [bis(4-chlorophenyl)-methyl]azetidin-3-yl}-4-methanesulfonylbenzamide (5-methylsulfonylthiophene-2-carboxy)-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}amide (5-methylsulfonyl-3-methyl-4-vinylthiophene-2 -carboxy){l-[bis-(4-chlorophenyl)-methyl]azetidin-3-yl}amide (5-methylsulfonyl-3-methyl-4-vinylthiophene-2 -carboxy){1-[bis(4-chlorophenyl)-methyl]azetidin-3-yl }.amide 65 N-{l-[bis(4-chlorophenyl)pyridin-3-ylmethyl]azetidin-3-yl}-3,5-difluorobenzenesulfonamide N-{1-[bis(4-Chlorophenyl)pyrimidin-5-ylmethyl]azetidin-3-yl}-3,5-difluorobenzenesulfonamide 5

8. Process for producing a compound as defined in claim 4 in which Ri represents a radical -NHCOR4, characterized in that an acid R4COOH for which R4 has the same meanings as in claim 5 is reacted with a 10 derivative of formula: 15 in which R2 and R3 are as defined in claim 4, the product isolated and optionally converted to a pharmaceutically acceptable salt.

9. Process for producing a compound as defined in claim 4 in which Ri represents a radical 20 -N(R5)-Y-Rs, characterized in that a derivative of formula: INTELLECTUAL PROPERTY OFFICE OF N.Z. - 9 jun 2004 rccciVCD 66 N \ NH2 in which R2 and R3 are as defined in claim 4 is reacted with a derivative Hal-Y-R6 for which Y and R6 are as defined in claim 4 and Hal represents a halogen atom, optionally followed by a derivative Hal-alk, Hal represents a halogen atom and alk represents an alkyl radical (1-6C in the form of a straight or branched chain) to give a compound in which R5 is an alkyl radical, the product isolated and optionally converted to a pharmaceutically acceptable salt. defined in claim 4, characterized in that a derivative R2-CHBr-R3 for which R2 and R3 have the same meanings as in claim 4 is reacted with a derivative of formula: in which Ri is as defined in claim 4, the product isolated and optionally converted to a pharmaceutically acceptable salt. defined in claim 4 for which Rx represents a radical -N(R5)-Y-R6 in which R6 is a phenyl radical substituted with a 1-pyrrolidinyl radical, characterized in that

10. Process for producing a compound as HN

11. Process for producing a compound as INTELLECTUAL PROPERTY OFFICE OF N.Z. -9 JUN 2004 67 pyrrolidine is reacted with a corresponding compound of formula (I) for which Rj. represents a radical -N(R5)-Y-R6 in which R6 is a phenyl radical substituted with a fluorine atom, the product isolated and optionally 5 converted to a pharmaceutically acceptable salt.

12. A process according to any one of claims 8 to 11 and substantially as hereinbefore described.

13. A compound produced by a process as claimed in any one of claims 8 to 12. 10

14. A pharmaceutical composition according to any one of claims 1 to 3 and substantially as hereinbefore described.

15. A compound according to claim 4 and specifically as hereinbefore mentioned. END OF CLAIMS INTELLECTUAL PROPERTY OFFICE OF N.Z. - 9 jun 2004 RECEIVED </div>